Arrowhead Pharmaceuticals and partner Johnson & Johnson provided the latest update to a Phase 2 study testing their experimental RNA interference therapy in patients with chronic hepatitis B infections.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,